These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24261554)

  • 1. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.
    Sommer JM; Moore N; McGuffie-Valentine B; Bardan S; Buyue Y; Kamphaus GD; Konkle BA; Pierce GF
    Haemophilia; 2014 Mar; 20(2):294-300. PubMed ID: 24261554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.
    Turecek PL; Romeder-Finger S; Apostol C; Bauer A; Crocker-Buqué A; Burger DA; Schall R; Gritsch H
    Haemophilia; 2016 Nov; 22(6):957-965. PubMed ID: 27353010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc).
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TAL; Walker ID
    Int J Lab Hematol; 2019 Apr; 41(2):176-183. PubMed ID: 30556650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
    Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.
    St Ledger K; Feussner A; Kalina U; Horn C; Metzner HJ; Bensen-Kennedy D; Blackman N; Veldman A; Stowers A; Friedman KD
    J Thromb Haemost; 2018 Mar; 16(3):555-564. PubMed ID: 29274194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.
    Tiefenbacher S; Clausen WHO; Hansen M; Lützhøft R; Ezban M
    Haemophilia; 2019 Sep; 25(5):893-901. PubMed ID: 31294905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
    Kitchen S; Beckmann H; Katterle Y; Bruns S; Tseneklidou-Stoeter D; Maas Enriquez M
    Haemophilia; 2016 May; 22(3):e192-9. PubMed ID: 27030173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
    Désage S; Nougier C; Meunier S; Chamouard V; Jousselme E; Dargaud Y; Lienhart A
    Haemophilia; 2024 Mar; 30(2):538-544. PubMed ID: 38149726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
    Ingerslev J; Jankowski MA; Weston SB; Charles LA;
    J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International comparative field study of N8 evaluating factor VIII assay performance.
    Viuff D; Barrowcliffe T; Saugstrup T; Ezban M; Lillicrap D
    Haemophilia; 2011 Jul; 17(4):695-702. PubMed ID: 21426445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.
    Sommer JM; Buyue Y; Bardan S; Peters RT; Jiang H; Kamphaus GD; Gray E; Pierce GF
    Thromb Haemost; 2014 Nov; 112(5):932-40. PubMed ID: 25144892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
    Kitchen S; Katterle Y; Beckmann H; Maas Enriquez M
    J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
    Peters RT; Toby G; Lu Q; Liu T; Kulman JD; Low SC; Bitonti AJ; Pierce GF
    J Thromb Haemost; 2013 Jan; 11(1):132-41. PubMed ID: 23205847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of Nuwiq
    Tiefenbacher S; Albisetti M; Baker P; Kappert G; Kitchen S; Kremer Hovinga JA; Pouplard C; Scholz U; Ternisien C; Borgvall C; Vicente T; Belyanskaya L; Walter O; Oldenburg J;
    Haemophilia; 2019 Jul; 25(4):708-717. PubMed ID: 31106957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards.
    Morfini M; Cinotti S; Bellatreccia A; Paladino E; Gringeri A; Mannucci PM;
    J Thromb Haemost; 2003 Nov; 1(11):2283-9. PubMed ID: 14629459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
    Peyvandi F; Oldenburg J; Friedman KD
    J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
    Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
    Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.
    Buyue Y; Liu T; Kulman JD; Toby GG; Kamphaus GD; Patarroyo-White S; Lu Q; Reidy TJ; Mei B; Jiang H; Pierce GF; Sommer JM; Peters RT
    PLoS One; 2014; 9(11):e113600. PubMed ID: 25415306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
    Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
    Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.